Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Medical Case Reports
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Pharmacokinetics | Case report

Ivabradine toxicity: a case report

Authors: Kavisha Singh, Muthukumar R. Alagarraju, Carl E. Wolf, Justin L. Poklis, Nitin Kulkarni, William Tharpe, Parag H. Joshi

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

We describe a case of symptomatic bradycardia resulting from ivabradine toxicity by measurement of ivabradine levels, of which there are limited reports in the literature.

Case presentation

A 43-year-old White female presented with several days of near syncope and dizziness accompanied by a drop in her heart rate to 50 beats per minute. She was taking ivabradine for inappropriate sinus tachycardia. After excluding several other causes of bradycardia, we made the diagnosis of ivabradine toxicity by measurement of serum ivabradine levels, an approach that is currently not clinically available.

Conclusions

Measurement of serum ivabradine levels and knowledge of the pharmacokinetic properties of the drug can be utilized to confirm the diagnosis of ivabradine toxicity.
Appendix
Available only for authorised users
Literature
1.
Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70(14):1777–84.CrossRef
2.
Mathiaux F, Dulaurent S, Julia F, Gaulier JM. Case report of ivabradine intoxication. J Anal Toxicol. 2014;38(4):231–2.CrossRef
3.
Osei K, Taskesen T, Goerbig-Campbell J, Hounshell T. Ivabradine toxicity: a case report and review. HeartRhythm Case Rep. 2020;6(4):183–6.CrossRef
4.
Maskell K, Tse A, Wolf CE, Troendle M. Acute on chronic ivabradine overdose: a case report. J Med Toxicol. 2016;12(2):189–91.CrossRef
5.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376(9744):875–85.CrossRef
6.
Fala L. Corlanor (ivabradine), first HCN channel blocker, FDA approved for the treatment of patients with heart failure. American health & drug benefits. 2016;9(Spec Feature):56.
7.
Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;2018:25701.
8.
Issa Z, Miller JM, Zipes DP. Clinical arrhythmology and electrophysiology: a companion to Braunwald’s heart disease e-book. Elsevier Health Sciences; 2012.
9.
Rosa GM, Ferrero S, Ghione P, Valbusa A, Brunelli C. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. Expert Opin Drug Metab Toxicol. 2014;10(2):279–91.CrossRef
10.
Kaur U, Chakrabarti SS, Singh B, Gambhir IS. A prospective observational pilot study of adverse drug reactions in patients admitted in the geriatric ward of a tertiary hospital in North India. Curr Pharmacogenomics Person Med. 2018;16(2):147–55.CrossRef
11.
Yabek SM, Swensson RE, Jarmakani J. Electrocardiographic recognition of sinus node dysfunction in children and young adults. Circulation. 1977;56(2):235–9.CrossRef
12.
Kramarz E, Makowski K. Clinical significance of second degree Wenckebach type sinoatrial block identified during Holter monitoring in patients with symptoms suggestive of arrhythmia. EP Europace. 2014;17(1):123–30.CrossRef
13.
Savelieva I, Camm AJ. If inhibition with ivabradine. Drug Saf. 2008;31(2):95–107.CrossRef
14.
Camm AJ, Lau C-P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R&D. 2003;4(2):83–9.CrossRef
15.
Kocabay G, Yildiz M, Eksi Duran N, Ozkan M. Sinus arrest due to sertraline. Clin Cardiol. 2010;33(6):E114–5.CrossRef
Metadata
Title
Ivabradine toxicity: a case report
Authors
Kavisha Singh
Muthukumar R. Alagarraju
Carl E. Wolf
Justin L. Poklis
Nitin Kulkarni
William Tharpe
Parag H. Joshi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-022-03554-w

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue

Case report

Diagnosis of tuberculosis with autoimmune hepatitis–systemic lupus erythematosus overlap syndrome: a case report

Case report

Postpartum spontaneous vulvar hematoma as a cause of maternal near miss: a case report and review of the literature

Case report

Acute ischemic stroke: a rare complication of hump-nosed pit viper (Hypnale spp.) bite: a case report

Case report

Low apparent diffusion coefficient in an extracranial brain tumor: a case report

Case report

Coats disease in adolescence and adulthood with preserved vision after laser photocoagulation monotherapy: two case reports

Case report

Severe thyrotoxicosis as initial presentation of gastric choriocarcinoma: a case report